Innoviva Inc INVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INVA is a good fit for your portfolio.
News
-
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
-
Innoviva to Participate in the Cantor Global Healthcare Conference
-
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
-
FDA approves Innoviva's bacterial pneumonia treatment
-
FDA Approves Innoviva's Bacterial Pneumonia Treatment
-
Innoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam
-
Innoviva Says FDA Accepts, Grants Priority Review for Infection Treatment SUL-DUR NDA
Trading Information
- Previous Close Price
- $13.69
- Day Range
- $13.66–13.96
- 52-Week Range
- $10.64–14.08
- Bid/Ask
- $13.64 / $14.06
- Market Cap
- $887.60 Mil
- Volume/Avg
- 496,643 / 685,338
Key Statistics
- Price/Earnings (Normalized)
- 10.64
- Price/Sales
- 4.27
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 7.83%
Company Profile
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 101
- Website
- https://www.inva.com
Competitors
Valuation
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.64 | 17.99 | 10.62 |
Price/Book Value | 1.42 | 5.38 | 1.77 |
Price/Sales | 4.27 | 4.48 | 2.54 |
Price/Cash Flow | 9.18 | 20.33 | 8.93 |
Price/Earnings
INVA
AZN
PFE
Financial Strength
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Quick Ratio | 6.85 | 0.60 | 1.90 |
Current Ratio | 8.43 | 0.79 | 2.38 |
Interest Coverage | 4.13 | 5.27 | 6.05 |
Quick Ratio
INVA
AZN
PFE
Profitability
|
Metric
|
INVA
|
AZN
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.97% | 61.67% | 8.04% |
Return on Equity (Normalized) | 12.13% | 162.15% | 16.96% |
Return on Invested Capital (Normalized) | 6.86% | 91.05% | 11.79% |
Return on Assets
INVA
AZN
PFE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xrdcq | $456.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sszgzl | $91.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Npgfsq | $89.8 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Kldbdmw | $40.2 Bil | |
MRNA
| Moderna Inc | Skspn | $29.6 Bil | |
ARGX
| argenx SE ADR | Nbym | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Zjptt | $23.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qvqxww | $21.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Cyqvmm | $17.2 Bil | |
INCY
| Incyte Corp | Gvzgnv | $12.2 Bil |